

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Health Technology Appraisal

Immunosuppressant therapy for the treatment of renal transplantation in children
(review of TA99)

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Astellas Pharma (tacrolimus) • Genzyme Therapeutics (thymoglobuline) • Novartis Pharmaceuticals (basiliximab, ciclosporin and mycophenolate sodium) • Roche Products (mycophenolate mofetil) • Wyeth Pharmaceuticals (sirolimus) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Children • Action for Sick Children • Afiya Trust • Association for Children with Life Threatening or Terminal Conditions • Black Health Agency • British Kidney Patient Association • British Organ Donor Society (BODY) • Children's Society • Chinese National Healthy Living Centre • Equalities National Council • Gift – The Children's Transplant Charity • Kidney Alliance • Kidney Research UK • Muslim Council of Great Britain • Muslim Health Network • National Children's Bureau • National Kidney Federation • National Parent and Carer Council • National Parent Partnership Network • South Asian Health Foundation • Specialised Healthcare Alliance • Transplant Support Network • Transplant Trust • WellChild <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Industries • Association of Renal Technologists • Association of Surgeons of Great Britain and Ireland 	<p><u>General</u></p> <ul style="list-style-type: none"> • Association of Welsh Community Health Councils • Board of Community Health Councils in Wales • Care Quality Commission • Commissioning Support Appraisal Service • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium • UK Transplant Support Service (NHS Special Health Authority) • Welsh Kidney Patients Association <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Actavis UK (azathioprine, prednisolone) • Alliance Pharmaceuticals (prednisolone) • Almus Pharmaceuticals (prednisolone) • Amdipharm (prednisolone) • Arrow Generics (azathioprine) • Aspen Europe GmbH (azathioprine) • Boots Company (prednisolone) • Co-pharma (azathioprine) • Dexcel Pharma (ciclosporin) • GlaxoSmithKline (azathioprine) • Janssen-Cilag (muronomab CD-3) • Kent Pharmaceuticals (azathioprine, prednisolone) • LPC Medical UK (prednisolone) • Mylan UK (azathioprine) • Norton Healthcare (azathioprine)

<ul style="list-style-type: none"> • British Association of Urological Surgeons • British Renal Society • British Transplantation Society • British Urological Foundation • Kidney Research UK • Renal Association • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatric and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicines • Society for DGH Nephrologists • UK Renal Pharmacy Group • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Devon • NHS South West Essex • Welsh Assembly Government 	<ul style="list-style-type: none"> • Novartis Pharmaceuticals UK (ciclosporin) • Pfizer (methylprednisolone) • Regiomedica GmbH (azathioprine) • Relonchem (azathioprine) • Sandoz UK (azathioprine) • Teva UK (azathioprine, prednisolone) • Tillomed (azathioprine) • Waymade (prednisolone) • Wockhardt UK (prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Centre for Reviews & Dissemination and Centre for Health Economics -York • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre for Acute and Chronic Conditions <p><u>Public Health Groups</u></p> <ul style="list-style-type: none"> • none
---	--

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality

Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, the *British National Formulary*, and the British Medical Association).

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).